Aerocrine AB (OMX Nordic Exchange: AERO) announces that Health Canada’s Therapeutic Products Directorate has authorized Aerocrine’s latest NIOX MINO® for use in identifying allergic airway ...
SOLNA, Sweden & ANTONY, France--(BUSINESS WIRE)--Aerocrine AB (STO:AERO.B) and Stallergenes S.A (Euronext Paris CAC small) today announce the signing of an exclusive multi-year distribution agreement ...
SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Aerocrine AB (STO:AERO-B), a leader in products to monitor and manage airway inflammation associated with Asthma, announced today that its handheld ...
SOLNA, Sweden, 12 February 2009 - Aerocrine AB (OMX Nordic Exchange: AERO) has reported the recent publication of a UK study evaluating the effect of routine inflammation measurement in asthma. The ...
March 11, 2008 — The US Food and Drug Administration (FDA) has granted 510(k) clearance for a handheld device for the measurement of airway inflammation, an intraosseous infusion system for use in ...
NEW PROVIDENCE, N.J., March 4 /PRNewswire/ -- Aerocrine, Inc. (www.aerocrine.com) today announced that NIOX MINO (www.nioxmino.com), a hand- held point-of-care device for the measurement of airway ...
Aerocrine secured $50 million in financing to market the Niox Mino.--Courtesy of Aerocrine Sweden's Aerocrine has secured $50 million in combined debt and equity financing, money the company will use ...
Aerocrine AB, a medical technology company focused on the improved management and care of patients with inflammatory airway diseases, has signed an distribution agreement with Shanghai Pharmaceuticals ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results